美金刚改善唐氏综合征青少年及年轻成人认知与适应性结局的安全性和耐受性:一项随机双盲安慰剂对照2期试验
这项在巴西和美国开展的随机双盲安慰剂对照2期试验纳入160名15-32岁唐氏综合征患者,评估美金刚20 mg/日治疗16周对情景记忆的影响。主要结局CVLT-II-sf总自由回忆评分变化组间无显著差异(变化0.34分,95%CI -0.98至1.67,p=0.61)。美金刚耐受性良好,不良事件多为轻中度,未观察到严重不良事件。
要点
- 美金刚20 mg/日治疗16周未显著改善唐氏综合征患者的情景记忆。
- 美金刚耐受性良好,常见不良事件为病毒性上呼吸道感染和一过性头晕。
- 探索性分析提示需未来进一步研究。
核心结论
- 美金刚耐受性良好,但20 mg/日剂量未在唐氏综合征青少年及年轻成人中记录到认知增强效应。
- 探索性分析提示需未来进一步研究。
研究设计与样本
- 随机、双盲、安慰剂对照、平行设计2期试验,按年龄和性别分层。
- 参与者为15-32岁、21三体或21号染色体完全不平衡易位且总体健康的唐氏综合征患者,从巴西一个中心和美國一个中心的社区招募。
- 参与者按1:1随机分配接受美金刚20 mg/日口服或安慰剂治疗16周。
- 主要结局为从基线至第16周加州言语学习测验第二版简版(CVLT-II-sf)总自由回忆评分的变化,在意向治疗方案人群(完成16周治疗且在T1和T2均有神经心理评估的参与者)中评估。
- 安全性和耐受性在所有开始治疗的参与者中监测和分析。
主要发现
- 2015年5月13日至2020年7月22日,185名唐氏综合征患者接受资格评估,160名(86%)被随机分配至美金刚组(n=81)或安慰剂组(n=79)。
- 线性混合效应模型拟合了149名(81%)参与者的数据,美金刚组73名,安慰剂组76名;11人(美金刚组8人,安慰剂组3人)因COVID-19限制、照护者生病、不良事件或依从性低而中止。
- 主要结局指标组间无差异(CVLT-II-sf总自由回忆评分,从基线变化0.34分,95%CI -0.98至1.67,p=0.61)。
- 美金刚耐受性良好,不良事件不频繁且为轻中度,最常见为病毒性上呼吸道感染(美金刚组9例[11%],安慰剂组12例[15%])和一过性头晕(美金刚组8例[10%],安慰剂组6例[8%])。
- 未观察到严重不良事件;美金刚血浆浓度显著低于阿尔茨海默病治疗认为有效的浓度。
临床怎么用
- 作者认为,美金刚20 mg/日剂量在唐氏综合征青少年及年轻成人中耐受性良好,但未记录到认知增强效应。
- 作者指出,探索性分析提示需未来进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Down syndrome is a chromosomal disorder with considerable neurodevelopmental impact and neurodegenerative morbidity. In a pilot trial in young adults with Down syndrome, memantine (a drug approved for Alzheimer's disease) showed a significant effect on a secondary measure of episodic memory. We aimed to test whether memantine would improve episodic memory in adolescents and young adults with Down syndrome. METHODS: We did a randomised, double-blind, placebo-controlled phase 2 trial with a parallel design, stratified by age and sex. Participants (aged 15-32 years) with either trisomy 21 or complete unbalanced translocation of chromosome 21 and in general good health were recruited from the community at one site in Brazil and another in the USA. Participants were randomly assigned (1:1) to receive either memantine (20 mg/day orally) or placebo for 16 weeks. Computer-generated randomisation tables for both sites (allocating a placebo or drug label to each member of a unique pair of participants) were centrally produced by an independent statistician and were shared only with investigational pharmacists at participating sites until unblinding of the study. Participants and investigators were masked to treatment assignments. Neuropsychological assessments were done at baseline (T1) and week 16 (T2). The primary outcome measure was change from baseline to week 16 in the California Verbal Learning Test-second edition short-form (CVLT-II-sf) total free recall score, assessed in the per-protocol population (ie, participants who completed 16 weeks of treatment and had neuropsychological assessments at T1 and T2). Linear mixed effect models were fit to data from the per-protocol population. Safety and tolerability were monitored and analysed in all participants who started treatment. Steady-state concentrations in plasma of memantine were measured at the end of the trial. This study is registered at ClinicalTrials.gov, number NCT02304302. FINDINGS: From May 13, 2015, to July 22, 2020, 185 participants with Down syndrome were assessed for eligibility and 160 (86%) were randomly assigned either memantine (n=81) or placebo (n=79). All participants received their allocated treatment. Linear mixed effect models were fit to data from 149 (81%) participants, 73 in the memantine group and 76 in the placebo group, after 11 people (eight in the memantine group and three in the placebo group) discontinued due to COVID-19 restrictions, illness of their caregiver, adverse events, or low compliance. The primary outcome measure did not differ between groups (CVLT-II-sf total free recall score, change from baseline 0·34 points [95% CI -0·98 to 1·67], p=0·61). Memantine was well tolerated, with infrequent mild-to-moderate adverse events, the most common being viral upper respiratory infection (nine [11%] participants in the memantine group and 12 [15%] in the placebo group) and transient dizziness (eight [10%] in the memantine group and six [8%] in the placebo group). No serious adverse events were observed. Amounts of memantine in plasma were substantially lower than those considered therapeutic for Alzheimer's disease. INTERPRETATION: Memantine was well tolerated, but cognition-enhancing effects were not recorded with a 20 mg/day dose in adolescents and young adults with Down syndrome. Exploratory analyses point to a need for future work. FUNDING: Alana Foundation. TRANSLATION: For the Portuguese translation of the abstract see Supplementary Materials section.
引用
- Costa ACS, Brandão AC, Boada R, et al. Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2022. PMID: 34942135. doi:10.1016/S1474-4422(21)00369-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。